CompletedNot Applicable

Patient Perceptions and Physician Assessment of Benefits and Risks of Oral Anticoagulation Due to Non-valvular AF

Austria91 participantsStarted 2015-09

Plain-language summary

The risk of stroke is markedly elevated in patients with atrial fibrillation (AF). Oral anticoagulation (OAC) is indicated in individuals with moderate and high risk of stroke to the disadvantage of an increased burden from bleeding. Adequate knowledge of this disorder and understanding the benefits and hazards of antithrombotic treatment are essential to incorporate patient´s values and preferences in these decisions. This will further improve acceptance of recommended therapy and augment compliance with OAC. The objective of this investigation is to compare patient´s perceptions and physician´s assessments of benefits and risks of OAC.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed and ECG-documented non-valvular atrial fibrillation * New indication for oral anticoagulation (OAC) * Ability of informed consent Exclusion Criteria: * Existing OAC therapy * Valvular heart disease * History of valve surgery

What they're measuring

Comparison of subjective stroke risk perception with CHA2DS2-VASc score

Timeframe: Baseline

Comparison of subjective bleeding risk perception with HAS-BLED score

Timeframe: Baseline

Trial details

NCT IDNCT03061123

SponsorMedical University of Graz

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-10

View on ClinicalTrials.gov More Atrial Fibrillation trials